75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight
DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...
Finanznachrichten21h
DelveInsight Business Research, LLP: 75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight
In September 2024, Sanofi announced the outcomes of Phase III clinical trials of its investigational oral brain-penetrant BTK inhibitor, tolebrutinib, aimed at treating multiple sclerosis (MS). These ...
FiercePharma8h
Say goodbye to BeiGene as the oncology biopharma becomes BeOne Medicines in rebrand
For the past three years, biotechs and pharmas have renamed, rebranded and more in a bid to refresh their corporate appeal. ...